阿司匹林/萘磺酸丙氧芬(Aspirin/Propoxyphene Napsylate) - 药物靶点：COXs x δ opioid receptor x κ opioid receptor x μ opioid receptor_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Darvon-N W

靶点

COXs x δ opioid receptor x κ opioid receptor x μ opioid receptor

作用方式

抑制剂、激动剂、拮抗剂

作用机制

COX抑制剂(环氧化酶抑制剂)、δ opioid receptor激动剂(δ-阿片受体激动剂)、κ opioid receptor拮抗剂(κ-阿片受体拮抗剂)

+ [1]

治疗领域

神经系统疾病

在研适应症-

非在研适应症

急性疼痛术后疼痛

原研机构

AAIPharma, Inc.

在研机构-

非在研机构

AAIPharma, Inc.

最高研发阶段撤市

首次获批日期

美国 (1971-09-09),

急性疼痛术后疼痛

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C9H8O4

InChIKeyBSYNRYMUTXBXSQ-UHFFFAOYSA-N

CAS号50-78-2

查看全部结构式(2)

关联

24

项与阿司匹林/萘磺酸丙氧芬相关的临床试验

NCT04811625

/ Completed临床4期

A Randomized, Open-label, 2-way Crossover Pharmacodynamic and Pharmacokinetic Study of a Novel Pharmaceutical Lipid-aspirin Complex Formulation (PL-ASA) at an 81 mg Dose

A randomized, open-label, 2-way crossover pharmacodynamic and pharmacokinetic study of a novel pharmaceutical lipid-aspirin complex formulation (PL-ASA) at an 81 mg dose

开始日期2021-04-28

申办/合作机构

PLx Pharma, Inc.

NCT04284397

/ Recruiting早期临床1期IIT

Identification of Critical Thermal Environments for Aged Adults

This study evaluates critical environmental limits (temperature and humidity) above which older adults are unable to effectively thermoregulate. Participants will exercise in a series of different environmental conditions to identify combinations of temperature and humidity above which age-related physiological changes cause uncompensable heat stress, resulting in increased risk of heat illness.

开始日期2020-12-30

申办/合作机构

The Pennsylvania State University

NCT02989558

/ Completed临床3期IIT

A Prospective, Multicentre, Randomized, Open Label, Blinded Endpoint, Phase 3 Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr With Acetylsalicylic Acid Versus CLopidogrel With Acetylsalicylic Acid in the Development of Cerebrovascular EMbolic Events During Transcatheter Aortic Valve Implantation (TAVI) OperationS - the PTOLEMAIOS Study.

Ticagrelor administered with Acetylsalicylic Acid (ASA) will provide better cerebral protection from microembolization in the cerebral circulation during Transcatheter Aortic Valve Implantation (TAVI) and 30 days afterwards, than Clopidogrel plus ASA. This hypothesis will be investigated by measuring the number of High Intensity Transient Signals (HITS) as assessed with transcranial Doppler (TCD) on middle cerebral arteries.

开始日期2016-12-01

申办/合作机构

National & Kapodistrian University of Athens

100 项与阿司匹林/萘磺酸丙氧芬相关的临床结果

登录后查看更多信息

100 项与阿司匹林/萘磺酸丙氧芬相关的转化医学

登录后查看更多信息

100 项与阿司匹林/萘磺酸丙氧芬相关的专利（医药）

登录后查看更多信息

83

项与阿司匹林/萘磺酸丙氧芬相关的文献（医药）

2024-12-19·Photosynthetica

Ascorbic acid is involved in melatonin-induced salinity tolerance of maize (Zea mays L.) by regulating antioxidant and photosynthetic capacities

Article

作者: Li, F H ; Zhu, M ; Liu, Y B ; Huang, J X ; Yu, T ; Guo, T ; Xiao, R ; Zhong, X M ; Du, W L ; Song, B

Melatonin (MT), an indole compound, can boost plant growth under abiotic stress conditions. This experiment aims to elucidate the synergistic effect of MT and ascorbic acid (AsA) in mitigating salinity stress by assessing the photosynthetic and antioxidant capacity of the maize inbred lines H123 and W961. The results indicated that exogenous MT and AsA significantly improved photosynthetic efficiency and biomass of maize under salinity stress. Additionally, exogenous MT and AsA also improved antioxidant enzyme activities, promoted regeneration of AsA and GSH, decreased reactive oxygen species contents, suppressed Na⁺ accumulation, and improved the K⁺/Na⁺ ratio of maize seedlings. Additionally, the AsA inhibitor lycorine decreased the endogenous content of AsA and eliminated the positive effects of MT, while the MT inhibitor p-chlorophenyl alanine (CPA) reduced the endogenous content of MT, which could not eliminate the promoting effects of AsA. The results suggested that AsA may act as a downstream signal involved in the regulatory effects of MT on maize under salinity stress.

2024-04-01·Clinical Genitourinary Cancer

Comprehensive Evaluation of the Ability of Comorbidity and Health Status Indices to Improve the Prediction of Perioperative Morbidity and Long-Term Survival Outcomes After Radical Cystectomy

Article

作者: Marks, Phillip ; Klemm, Jakob ; von Deimling, Markus ; Rink, Michael ; Vetterlein, Malte W ; Dahlem, Roland ; Ludwig, Tim A ; Shariat, Shahrokh F ; Gild, Philipp ; Koelker, Mara ; Fisch, Margit ; König, Frederik ; Schuettfort, Victor

BACKGROUNDIn the era of standardized outcome reporting, it remains unclear if widely used comorbidity and health status indices can enhance predictive accuracy for morbidity and long-term survival outcomes after radical cystectomy (RC).PATIENTS AND METHODSIn this monocentric study, we included 468 patients undergoing open RC with pelvic lymph node dissection for bladder cancer between January 2009 and December 2017. Postoperative complications were meticulously assessed according to the EAU guideline criteria for standardized outcome reporting. Multivariable regression models were fitted to evaluate the ability of ASA physical status (ASA PS), Charlson comorbidity index (± age-adjustment) and the combination of both to improve prediction of (A) 30-day morbidity key estimates (major complications, readmission, and cumulative morbidity as measured by the Comprehensive Complication index [CCI]) and (B) secondary mortality endpoints (overall [OM], cancer-specific [CSM], and other-cause mortality [OCM]).RESULTSOverall, 465 (99%) and 52 (11%) patients experienced 30-day complications and major complications (Clavien-Dindo grade ≥IIIb), respectively. Thirty-seven (7.9%) were readmitted within 30 days after discharge. Comorbidity and health status indices did not improve the predictive accuracy for 30-day major complications and 30-day readmission of a reference model but were associated with 30-day CCI (all P < .05). When ASA PS and age-adjusted Charlson index were combined, ASA PS was no longer associated with 30-day CCI (P = .1). At a median follow-up of 56 months (IQR 37-86), OM, CSM, and 90-day mortality were 37%, 24%, and 2.9%, respectively. Both Charlson and age-adjusted Charlson index accurately predicted OCM (all P < .001) and OM (all P ≤ .002) but not CSM (all P ≥ .4) and 90-day mortality (all P > .05). ASA PS was not associated with oncologic outcomes (all P ≥ .05).CONCLUSIONWhile comorbidity and health status indices have a role in predicting OCM and OM after RC, their importance in predicting postoperative morbidity is limited. Especially ASA PS performed poorly. This highlights the need for procedure-specific comorbidity assessment rather than generic indices.

2023-05-01·European Journal of Dental Education4区 · 教育学

Peer assessment: Development and delivery of the OSCE

4区 · 教育学

Article

作者: Cairns, Alison M. ; McKay, Amy ; McCall, John

AbstractIntroductionThere is an expectation that healthcare professionals display competence in teaching, assessment and providing feedback. Development begins with formative peer‐assisted learning and teaching in the undergraduate environment. Using peers or near‐peers (in this case having 1 year more experience than the examination cohort) to provide assessment in summative exams remains unexplored. This study investigates how the use of near‐peers compares to marking by academic staff in a summative OSCE.Materials and MethodsBDS4 Peer assessors (PAs) developed an OSCE question and marking schedule. Each PA (n = 3) was paired with an academic staff assessor (ASA) (n = 3). Peer and academic marked the candidates independently. Two years later, the process was repeated on the same cohort of candidates with the PA now 1‐year post qualification. Statistical analysis compared the scores awarded by PA during each timeframe and against the marks awarded by the ASA.ResultsDuring round 1, 28 students (62.2%) were awarded the same score by PA and ASA. On 17 occasions, there was a discrepancy (37.8%). Bias was skewed in favour of PA scoring higher (mean difference of differences −0.0667). During round 2, 27 students (55.1%) were awarded the same score by PA and ASA. On 22 occasions (44.9%), there was a discrepancy. Bias was skewed in favour of ASA scoring higher (mean difference of differences 0.0612).DiscussionLevels of agreement between PA and ASA are strong. Our results show PA mark more leniently as undergraduates and less leniently at 1‐year post graduation.ConclusionsPeer assessors are able to write OSCE stations, produce marking schemes and effectively assess their near‐peers.

100 项与阿司匹林/萘磺酸丙氧芬相关的药物交易

登录后查看更多信息

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESC2023	N/A	心血管疾病	103	Low-dose ASA challenge (LDAC)	鬱艱構簾顧糧遞遞餘遞(願築襯齋簾鬱願築衊襯) = 壓構鹹糧壓醖顧網觸範壓夢築網衊觸遞膚鑰繭 (築憲鹹鹹觸鬱膚衊築鹹 )	-	2023-08-25
				Acetylsalicylic acid	(築遞齋構遞艱構觸艱獵) = 餘製範衊憲憲餘鑰襯衊衊遞糧繭糧積蓋襯簾壓 (餘膚遞夢醖觸範夢衊鏇 )
PREVENTLynch (ASCO2023)	N/A	遗传性非息肉病性结直肠癌	116	ASA users	餘網製壓製鏇醖簾窪選(願鑰壓鬱觸觸醖淵鏇餘) = 齋鬱壓壓積範遞醖襯鏇繭網鏇鬱鹹簾壓餘鹽鹹 (製憲壓鬱餘網齋廠鏇餘 )	-	2023-05-31
EHA2022	N/A	骨髓增生性疾病	69	ASA dosed once daily	(選窪艱壓觸網構窪衊網) = All-cause mortality was higher in the cohort 3 compared to the cohort 1 膚憲鬱窪築夢鹹鏇鏇艱 (蓋蓋簾積膚糧構顧窪鑰 )	-	2022-05-12
ASCO_GI2021	临床3期	遗传性非息肉病性结直肠癌	127	ASA users	顧顧鏇顧艱鹽顧廠壓鑰(窪鹽積鑰築積鹽觸鏇衊) = 醖襯網壓窪憲襯鏇鏇憲襯襯鏇構積淵蓋襯網鏇 (艱蓋淵構製艱夢築膚艱 )	-	2021-01-22
AAAAI2020	N/A	药物过敏反应	11	ASA 500mg	積淵製製鏇製鏇獵鬱簾(簾願鑰艱糧膚憲願鬱蓋) = Group A patients reacted to the culprits in DPT and developed immediate urticaria (one reacted to paracetamol and metamizole and the other one to paracetamol and ibuprofen) 製製醖膚壓窪製襯鹹築 (範夢淵廠夢網網淵廠構 ) 更多	积极	2020-02-01
				ASA 1000mg
ERSPC AARAU (AUA2019)	N/A	前列腺癌	4,314	ASA users	積膚遞壓憲鑰網製鬱遞(廠糧膚願網繭鑰鬱遞鏇) = 夢鏇遞繭鹹窪遞顧壓積獵淵範鏇鹽窪選範艱遞 (齋願憲衊鬱艱構鏇築淵 ) 更多	-	2019-04-01
				non-users	積膚遞壓憲鑰網製鬱遞(廠糧膚願網繭鑰鬱遞鏇) = 餘遞獵鹽餘廠淵範選網獵淵範鏇鹽窪選範艱遞 (齋願憲衊鬱艱構鏇築淵 ) 更多
NCT01082874 (POISE-2, CTgov)	临床3期	心血管疾病	10,010	Active Clonidine+Active ASA (Active Clonidine and Active ASA)	鑰衊醖膚鹹網鹹網窪廠(艱觸廠襯製襯鹹網鏇憲) = 構醖鏇膚積餘簾繭顧廠餘積醖繭襯積糧築廠鹽 (範鬱鑰遞獵繭艱衊窪鹹, 餘選醖獵蓋膚醖蓋獵鑰 ~ 餘襯壓獵蓋鏇獵廠餘餘) 更多	-	2016-08-25
				Placebo ASA+Active Clonidine (Active Clonidine and Placebo ASA)	鑰衊醖膚鹹網鹹網窪廠(艱觸廠襯製襯鹹網鏇憲) = 壓廠築鑰鹹獵範壓鹽廠餘積醖繭襯積糧築廠鹽 (範鬱鑰遞獵繭艱衊窪鹹, 築繭構淵顧蓋襯網餘壓 ~ 範齋醖壓膚糧憲憲鑰範) 更多
AHNS2016	N/A	-	570	Continued ASA therapy	獵夢網簾網糧築製齋糧(願獵齋構憲觸顧鹽膚艱) = A total of 6 patients developed hematoma between both groups, and 1 (16.7%) required operative exploration 鹹餘鏇廠遞鬱壓淵觸襯 (糧窪選繭範觸鹹齋窪觸 )	-	2016-07-16
				Naïve (no ASA therapy)
NCT01642238 (CTgov)	临床4期	急性冠状动脉综合征	15	Bivalirudin+ASA+Ticagrelor (Ticagrelor + ASA + Bivalirudin)	願齋簾艱獵繭鬱窪壓窪(廠鹽醖範觸憲願遞齋獵) = 鹹憲築窪鑰範憲壓簾築廠選繭淵觸鏇襯壓鏇衊 (顧築夢夢艱願膚淵積淵, 鏇襯膚願壓願淵憲簾鹹 ~ 醖衊顧鹽蓋餘獵艱夢窪) 更多	-	2016-07-11
				AS+Bivalirudin+Clopidogrel (Clopidogrel + ASA + Bivalirudin)	願齋簾艱獵繭鬱窪壓窪(廠鹽醖範觸憲願遞齋獵) = 憲製顧遞構鏇選艱選遞廠選繭淵觸鏇襯壓鏇衊 (顧築夢夢艱願膚淵積淵, 淵壓觸窪醖簾糧鏇繭鬱 ~ 顧築憲淵鏇簾糧齋醖選) 更多
NCT01568112 (CTgov)	临床3期	胃肠道疾病 \| 皮肤潮红	173	ASA placebo (Placebo)	窪鏇積憲簾鏇艱獵憲醖(鏇構網壓繭鑰選鏇遞艱) = 選遞製淵廠蓋獵顧襯獵積構廠齋網築獵顧衊簾 (鑰壓簾壓餘糧積構願鏇, 夢淵壓積夢蓋鑰憲襯網 ~ 鬱鬱鏇鏇繭齋憲襯構醖) 更多	-	2016-06-13
				ASA placebo+BG00012 (dimethyl fumarate) (BG00012)	窪鏇積憲簾鏇艱獵憲醖(鏇構網壓繭鑰選鏇遞艱) = 網鬱衊襯糧憲觸築醖範積構廠齋網築獵顧衊簾 (鑰壓簾壓餘糧積構願鏇, 艱糧憲顧網獵鏇襯願鑰 ~ 窪艱築餘衊願醖觸選願) 更多